Results 21 to 30 of about 111,040 (333)

Long-term platelet priming after glycoprotein VI stimulation in comparison to Protease-Activating Receptor (PAR) stimulation. [PDF]

PLoS ONE, 2021
Platelets can respond to multiple antagonists and agonists, implying that their activation state is a consequence of past exposure to these substances.
Jinmi Zou, Jiayu Wu, Mark Roest, Johan W M Heemskerk   +3 more
doaj   +2 more sources

Glenzocimab does not impact glycoprotein VI-dependent inflammatory hemostasis

Haematologica, 2020
Not available.
Soumaya Jadoui, Ophélie Le Chapelain, Véronique Ollivier, Ali Mostefa-Kara, Lucas Di Meglio, Sébastien Dupont, Angèle Gros, Mialitiana Solo Nomenjanahary, Jean-Philippe Desilles, Mikaël Mazighi, Bernhard Nieswandt, Stéphane Loyau, Martine Jandrot-Perrus, Pierre H Mangin, Benoit Ho-Tin-Noé   +14 more
doaj   +7 more sources

Is glycoprotein VI involved in contractual negotiations? [PDF]

Res Pract Thromb Haemost
Brysland SA, Hearn JI, Gardiner EE.
europepmc   +3 more sources

ADPase CD39 Fused to Glycoprotein VI‐Fc Boosts Local Antithrombotic Effects at Vascular Lesions [PDF]

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2017
BackgroundGPVI (Glycoprotein VI) is the essential platelet collagen receptor in atherothrombosis. Dimeric GPVI‐Fc (Revacept) binds to GPVI binding sites on plaque collagen. As expected, it did not increase bleeding in clinical studies.
Heidrun Degen, Oliver Borst, Melanie Ziegler, Ann‐Katrin Mojica Munoz, Janina Jamasbi, Britta Walker, Silvia Göbel, Julia Fassbender, Kristin Adler, Richard Brandl, Götz Münch, Reinhard Lorenz, Wolfgang Siess, Meinrad Gawaz, Martin Ungerer   +14 more
doaj   +2 more sources

Glycoprotein VI Blockade: Not Just Targeting Collagen Anymore? [PDF]

Arterioscler Thromb Vasc Biol, 2020
Gupta S, Brass LF.
europepmc   +5 more sources

Novel Ligands for Platelet Glycoprotein VI [PDF]

Thrombosis and Haemostasis, 2018
Meinrad Gawaz
openalex   +5 more sources

Sequence-specific 2'-O-methoxyethyl antisense oligonucleotides activate human platelets through glycoprotein VI, triggering formation of platelet-leukocyte aggregates

Haematologica, 2021
Antisense oligonucleotides (ASO) are DNA-based, disease-modifying drugs. Clinical trials with 2'-O-methoxyethyl (2’MOE) ASO have shown dose- and sequence-specific lowering of platelet counts according to two phenotypes.
Martina H. Lundberg Slingsby, Prakrith Vijey, I-Ting Tsai, Harvey Roweth, Genevieve Couldwell, Adrian R. Wilkie, Hans Gaus, Jazana M. Goolsby, Ross Okazaki, Brooke E. Terkovich, John W. Semple, Jonathan N. Thon, Scott P. Henry, Padmakumar Narayanan, Joseph E. Italiano Jr.   +14 more
doaj   +1 more source

Platelet calcium signaling by G-protein coupled and ITAM-linked receptors regulating anoctamin-6 and procoagulant activity

Platelets, 2021
Most agonists stimulate platelet Ca2+ rises via G-protein coupled receptors (GPCRs) or ITAM-linked receptors (ILRs). Well studied are the GPCRs stimulated by the soluble agonists thrombin (PAR1, PAR4), ADP (P2Y1, P2Y12), and thromboxane A2 (TP ...
Delia I. Fernández, Marijke J. E. Kuijpers, Johan W. M. Heemskerk   +2 more
doaj   +1 more source

Full genome sequence-based comparative study of wild-type and vaccine strains of infectious laryngotracheitis virus from Italy [PDF]

, 2016
Infectious laryngotracheitis (ILT) is an acute and highly contagious respiratory disease of chickens caused by an alphaherpesvirus, infectious laryngotracheitis virus (ILTV).
Franchin, Elisa, Lavezzo, Enrico, Massi, P., Moreno, A., Niero, Giulia, Palu', Giorgio, Piccirillo, Alessandra, Salata, Cristiano, Toppo, Stefano   +8 more
core   +11 more sources

The future of glycoprotein VI as an antithrombotic target [PDF]

Journal of Thrombosis and Haemostasis, 2012
The treatment of acute coronary syndromes has been considerably improved in recent years with the introduction of highly efficient antiplatelet drugs. However, there are still significant limitations: the recurrence of adverse vascular events remains a problem, and the improvement in efficacy is counterbalanced by an increased risk of bleeding, which ...
Pierre Mangin, Pierre Mangin, Philippe Billiald, Martine Jandrot-Perrus, Martine Jandrot-Perrus, Béatrice Hechler, Béatrice Hechler, M. Zahid, Christian Gachet, Christian Gachet, Stéphane Loyau, Stéphane Loyau   +11 more
openaire   +3 more sources